A phase ii study of capecitabine (c), oxaliplatin (o) and bevacizumab (b) using a 2-weekly schedule in previously untreated patients (pts) with advanced, unresectable colorectal cancer (crc) - cancer trials new zealand study 05-6

A phase ii study of capecitabine (c), oxaliplatin (o) and bevacizumab (b) using a 2-weekly schedule in previously untreated patients (pts) with advanced, unresectable colorectal cancer (crc) - cancer trials new zealand study 05-6

Findlay, Michael ; Sharples, KJ ; Thompson, PI ; Perez, DJ ; Adams, J ; Isaacs, R ; Robinson, B ; Hinder, Victoria ; Pollard, S ; O'Donnell, AE
Identifier: http://hdl.handle.net/2292/18840
Issue Date: 2008-09-01
Reference: Annals of Oncology 19(Supplement 8):129-130 01 Sep 2008
Rights: Copyright: European Society for Medical Oncology
Rights (URI): https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm

Abstract:

Improved progression-free survival (PFS) in CRC pts has been observed using a modified 2-week CO schedule [Scheithauer et al. J Clin Oncol 2003;21:1307– 12] and the TREE-2 study indicated that B adds little toxicity to these drugs [Hochster et al. J Clin Oncol 2006;24(18S):3510]. This phase II study determined the feasibility of the combination C (1.75g/m2 BD days 1-7), O and B using a 14-day cycle for pts with advanced, unresectable CRC.

Show full item record

Files in this item

Icon
DOI: 10.1093/annonc/mdn507
Icon
Related URL: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000259973300372&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e41486220adb198d0efde5a3b153e7d
Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics